Medicine, Rheumatology Division

Grants

Grants per year 1993 2002 2003 2005 2007 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2019 2020 2031

• 59 Active
• 488 Finished

Grants per year

Search results

• Prot# 016.0035: Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 2)

  Ruderman, E. M. (PD/PI)

  Immunex Corporation

  10/29/02 → 12/1/07

  Project: Research project

• Prot# 016.0037: Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 3 Study of Etanercept in the Treatment of Patients with Ankylosing Spondylitis

  Ruderman, E. M. (PD/PI)

  Immunex Corporation

  12/4/01 → 6/30/03

  Project: Research project

• Prot# 016.0040: Open-Label, Long-Term Extension Study of Etanercept in the Treatment of Patients with Ankylosing Spondylitis Who Participated in Protocol 016.0037

  Ruderman, E. M. (PD/PI)

  Immunex Corporation

  7/1/02 → 9/13/10

  Project: Research project

• Prot# 02-021: The CORRONA Data Collection Program (#02-021)

  Ruderman, E. M. (PD/PI)

  Corrona, LLC

  2/6/05 → 12/31/22

  Project: Research project

• Prot# 061-00/COX523: A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.I.d. in Patients with Osteoarthritis

  Ruderman, E. M. (PD/PI)

  Merck & Co., Inc.

  10/18/02 → 10/18/05

  Project: Research project

• Prot# 102-21: An Open Label Study of the Efficacy and Safety of Re-Treatments with Rituximab (MabThera®/Rituxan®) in Patients with Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies

  Ruderman, E. M. (PD/PI)

  Biogen Inc.

  6/23/04 → 9/9/10

  Project: Research project

• Prot# 104RA203: A Phs 2b, Rndmzd, Dbl-Blnd, Plcb-Cntrlld, Mltcntr Stdy to Evlut the Effcy, Sfty, Pharmacokinetics, and Pharmacodynamics of BG9924 When Gvn in Cmbntn w/ Methotrexate to Subs w/ Actv Rheumatoid Arthritis Who Have Had an Indqut Rspnd to Anti-

  Ruderman, E. M. (PD/PI)

  PPD Development, Biogen Inc.

  8/7/07 → 8/7/10

  Project: Research project

• Prot# 104RA203: A Phs 2b, Rndmzd, Dbl-Blnd, Plcb-Cntrlld, Mltcntr Stdy to Evlut the Effcy, Sfty, Pharmacokinetics, and Pharmacodynamics of BG9924 When Gvn in Cmbntn w/ Methotrexate to Subs w/ Actv Rheumatoid Arthritis Who Have Had an Indqut Rspnd to Anti-

  Ruderman, E. M. (PD/PI)

  PPD Development, Biogen Inc.

  8/7/07 → 8/7/10

  Project: Research project

• Prot# 104RA205: An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination with Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA203

  Ruderman, E. M. (PD/PI)

  PPD Development, Biogen Inc.

  9/5/07 → 9/5/10

  Project: Research project

• Prot#11-216: Treating to Target (T2T) for Patients with Rheumatoid Arthritis in a US Population: Outcomes and Feasibility

  Ruderman, E. M. (PD/PI)

  Corrona, LLC

  1/19/12 → 1/19/15

  Project: Research project

• Prot# 120-20: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Who Have Had an Inadequeate Respo

  Ruderman, E. M. (PD/PI)

  IDEC Pharmaceuticals Corporation

  5/6/03 → 9/10/10

  Project: Research project

• Prot #12-RA1: Cell Bound Complement activation products for the Monitoring of Systemic Lupus Erythematosus

  Ramsey-Goldman, R. (PD/PI)

  Exagen Diagnostics, Inc.

  1/7/13 → 1/7/16

  Project: Research project

• Prot# 13G01: A Phase 1 Dose Escalation Study of Repeat Intra-Articular Administration of tgAAC94, A Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonist

  Ruderman, E. M. (PD/PI)

  Targeted Genetics Corporation

  1/23/06 → 9/9/10

  Project: Research project

• Prot# 15201: Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Administered Intravenously in Subjects with Idiopathic Inflammatory Myopathy (Polymyositis and Dermatomyositis)

  Ruderman, E. M. (PD/PI)

  Trubion Pharmaceuticals Inc.

  11/30/05 → 1/4/07

  Project: Research project

• Prot# 16.0023: Open-Label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trial 016.0012

  Ruderman, E. M. (PD/PI)

  Immunex Corporation

  12/4/00 → 9/10/10

  Project: Research project

• Prot# 20030236: A Phase 4, Open-Label, Single-Arm, Observational Study Evaluating The Effectiveness and Safety of Enbrel® (etanercept) 50mg Once Weekly in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (infliximab)

  Ruderman, E. M. (PD/PI)

  Amgen, Inc.

  7/9/04 → 9/10/10

  Project: Research project

• Prot# 20040275: A Multi-Center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

  Ruderman, E. M. (PD/PI)

  Amgen, Inc.

  7/31/06 → 10/31/06

  Project: Research project

• Prot# 20040275: A Multi-Center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

  Ruderman, E. M. (PD/PI)

  Amgen, Inc.

  7/31/06 → 10/31/06

  Project: Research project

• Prot #20110144: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2

  Ruderman, E. M. (PD/PI)

  Amgen, Inc.

  5/5/14 → 5/5/17

  Project: Research project

• Prot #2012087: Characterization of Immune Alterations in Systemic Lupus Erythematosus (SLE) using Single Cell Network Profiling (SCNP)

  Ramsey-Goldman, R. (PD/PI)

  Nodality, Inc.

  8/7/13 → 8/7/15

  Project: Research project

• Prot #20130207: A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis

  Ruderman, E. M. (PD/PI)

  Immunex Corporation

  6/1/15 → 6/1/18

  Project: Research project

• Prot #2014.009.01: Efficacy and Safety of AbGn-168H in Patients with Active Psoriatic Arthritis: a 24-Week, Open-Label, Multi-center, Phase II Proof of Principle Trial

  Ruderman, E. M. (PD/PI)

  Advanced Clinical LLC, AbGenomics B.V.

  3/19/15 → 3/19/18

  Project: Research project

• Prot #22-RA1-TIGER: Treatment StratIfication Using Gene Expression Profiling in Rheumatoid Arthritis

  Mandelin, A. M. (PD/PI)

  Exagen Diagnostics, Inc.

  6/13/23 → 9/13/24

  Project: Research project

• Prot# 2315IL/0004: An Open, Mulicentre, Long-Term Follow-Up Study to Assess the Safety of Patients who Complete or Discontinue Early from Treatment in Any Study Involving ZD2315 (Study Code #SC-315-5261)

  Ruderman, E. M. (PD/PI)

  AstraZeneca LP

  11/14/01 → 5/24/07

  Project: Research project

• Prot# 2315IL/0004: An Open, Mulicentre, Long-Term Follow-Up Study to Assess the Safety of Patients who Complete or Discontinue Early from Treatment in Any Study Involving ZD2315 (Study Code #SC-315-5261)

  National Science Foundation

  11/14/01 → 5/24/07

  Project: Research project